Last updated: 11/03/2018 12:06:13
Analysis of expression of specific markers and their prognostic significance in hepatocellular carcinoma
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: Analysis of the incidence of expression of tumor antigens and tumor marker in cancer tissue from Asian patients with hepatocellular carcinoma and evaluation of prognostic significance of these tumor antigens.
Trial description: Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these. As a first step in the development of novel therapies, expression analysis of specific markers, including tumor antigens will be carried out, and the correlation of expression with disease variables and clinical outcome will be assessed. This will be done retrospectively using archived hepatocellular carcinoma tissue samples.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
The proportion of hepatocellular carcinoma patients whose tumor tissue expresses specific tumor antigens.
Timeframe: At the time of analysis
The prognostic character of the expression of the tumor antigens
Timeframe: At the time of analysis
Expression of c-MET in the same hepatocellular carcinoma tumor samples
Timeframe: At the time of analysis
Secondary outcomes:
Not applicable
Interventions:
Other: Retrospective analysis of already archived samples
Enrollment:
200
Observational study model:
Case-Only
Primary completion date:
2009-18-03
Time perspective:
Retrospective
Clinical publications:
Not applicable
Medical condition
Hepatocellular carcinoma
Product
GSK1711805A
Collaborators
Not applicable
Study date(s)
November 2008 to March 2009
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
Not applicable+ years
Accepts healthy volunteers
No
- The patient has pathologically proven hepatocellular carcinoma (any stage)
- All the data required are available from patient’s records
- N/A
Inclusion and exclusion criteria
Inclusion criteria:
- The patient has pathologically proven hepatocellular carcinoma (any stage)
- All the data required are available from patient’s records
Exclusion criteria:
- N/A
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
2009-18-03
Actual study completion date
2009-18-03
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website